The report "Hemostats Market by Product (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Gynecology, Neurology, Cardiovascular, Reconstructive), Formulation (Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2023", The hemostats market is expected to reach USD 3.03 billion by 2023 from USD 2.27 billion in 2018, at a CAGR of 6.0%.
Don’t miss out on business opportunities in Hemostats Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=9571619
“The thrombin-based hemostats segment is expected to account for the largest share of the market in 2018.”
Based on product, the hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. Of all these product segments, the thrombin-based hemostats segment is expected to account for the largest share of the global hemostats market in 2018.
“In 2018, the orthopedic surgery segment is expected to dominate the hemostats market”
On the basis of application, the hemostats market is segmented neurological surgery, cardiovascular surgery, general surgery, orthopedic surgery, gynecological surgery, reconstructive surgery, and other surgeries. The orthopedic surgery segment is expected to account for the largest share of the hemostats market in 2018.
Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619
CR Bard, Inc. (US), B. Braun Melsungen AG (Germany), Baxter International, Inc. (US), Integra LifeSciences (US), Marine Polymer Technologies, Inc. (US), Teleflex (US), Ethicon, Inc. (US), Pfizer, Inc. (US), Z-Medica LLC (US), and Gelita Medical GmbH (Germany).
Johnson & Johnson held the leading position in the global hemostats market in 2017. Ethicon, a subsidiary of Johnson & Johnson develops, manufactures, and markets technologically innovative hemostats. The company’s broad product portfolio includes surgical snow absorbable hemostats, surgicel fibrillar absorbable hemostats, surgicel nu-knit absorbable hemostats, and surgicel powder absorbable hemostats, among other products. The company has a strong presence across the globe with direct distribution channels in key markets. A good brand image for hemostats in the market has helped the company to maintain its leading position in the market. Ethicon focuses on expanding its presence in the hemostats market through the product launches. In June 2017, the company launched SURGICEL powder, a new absorbable adjunctive hemostat.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=9571619